Denali Therapeutics DNLI
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Denali Therapeutics (DNLI) Core Market Data and Business Metrics
Latest Closing Price
$13.74Price-Earnings Ratio
-4.98Total Outstanding Shares
145.22 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
161 Oyster Point Blvd., South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,668,712 Shares | 6.3 | 3/14/2025 | 10,505,627 Shares |
| 935,609 Shares | 9.51 | 2/28/2025 | 8,893,475 Shares |
| 868,341 Shares | 10 | 2/14/2025 | 8,685,245 Shares |
| 899,763 Shares | 8.6 | 1/31/2025 | 7,736,705 Shares |
| 1,166,770 Shares | 6.83 | 1/15/2025 | 7,968,985 Shares |
| 1,079,383 Shares | 7.26 | 12/31/2024 | 7,838,984 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-57.38 Million |
| Net Cash Flow From Operating Activities, Continuing | $-362.64 Million |
| Net Cash Flow From Investing Activities | $-187.92 Million |
| Net Cash Flow From Investing Activities, Continuing | $-187.92 Million |
| Net Cash Flow From Operating Activities | $-362.64 Million |
| Net Cash Flow, Continuing | $-57.38 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-308.02 Million |
| Other Operating Expenses | $100.15 Million |
| Basic Average Shares | $487.99 Million |
| Operating Expenses | $504.60 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Basic Earnings Per Share | $-2.76 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $6.18 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-421.31 Million |
| Comprehensive Income/Loss Attributable To Parent | $-421.31 Million |
| Comprehensive Income/Loss | $-421.31 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $534.35 Million |
| Accounts Payable | $9.59 Million |
| Equity Attributable To Parent | $1.32 Billion |
| Other Current Liabilities | $62.63 Million |
| Noncurrent Liabilities | $48.42 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||